Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug ...
Eisai has presented new clinical data from a post-hoc sub-group analysis of the Clarity AD open-label extension for lecanemab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback